These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36495582)

  • 1. Does antithrombotic use enable earlier diagnosis of bladder cancer? A brief institutional assessment.
    Shah YB; Clark CB; Shumaker A; Denisenko AA; Alfonsi S; Prebay Z; Schultz J; Mico V; Swaminathan V; Wang R; Mark JR; Trabulsi EJ; Lallas CD; Mann MJ; Goldberg H; Chandrasekar T
    Can J Urol; 2022 Dec; 29(6):11391-11393. PubMed ID: 36495582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.
    Moschini M; Karnes RJ; Suardi N; Bianchi M; Pellucchi F; Rocchini L; Damiano R; Serretta V; Salonia A; Montorsi F; Briganti A; Colombo R
    Clin Genitourin Cancer; 2016 Jun; 14(3):e245-50. PubMed ID: 26382220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.
    Ramirez D; Gupta A; Canter D; Harrow B; Dobbs RW; Kucherov V; Mueller E; Streeper N; Uhlman MA; Svatek RS; Messing EM; Lotan Y
    BJU Int; 2016 May; 117(5):783-6. PubMed ID: 26435378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.
    Ekici M; Demir E; Aydin C; Çağlayan MS; Özgür BC; Baykam MM
    Medicine (Baltimore); 2024 May; 103(20):e38228. PubMed ID: 38758868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications.
    Wallis CJD; Juvet T; Lee Y; Matta R; Herschorn S; Kodama R; Kulkarni GS; Satkunasivam R; Geerts W; McLeod A; Narod SA; Nam RK
    JAMA; 2017 Oct; 318(13):1260-1271. PubMed ID: 28973248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
    Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
    Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the association between the urinary microbiome and bladder cancer: An exploratory study.
    Hussein AA; Elsayed AS; Durrani M; Jing Z; Iqbal U; Gomez EC; Singh PK; Liu S; Smith G; Tang L; Guru KA
    Urol Oncol; 2021 Jun; 39(6):370.e9-370.e19. PubMed ID: 33436328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heavy Cigarette Smoking and Aggressive Bladder Cancer at Initial Presentation.
    Pietzak EJ; Mucksavage P; Guzzo TJ; Malkowicz SB
    Urology; 2015 Nov; 86(5):968-72. PubMed ID: 26190088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of secondary muscle-invasive bladder cancer.
    Hidas G; Pode D; Shapiro A; Katz R; Appelbaum L; Pizov G; Zorn KC; Landau EH; Duvdevani M; Gofrit ON
    BMC Urol; 2013 May; 13():23. PubMed ID: 23656972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
    Abdelgawad A; Hashem A; Mosbah A; Eissa LA
    PLoS One; 2022; 17(6):e0266371. PubMed ID: 35709298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
    Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
    Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
    Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
    Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
    Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
    World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.